12:12 PM
 | 
Oct 10, 2018
 |  BC Extra  |  Company News

Roche gets option to Ionis' antisense dry AMD candidate

Roche (SIX:ROG; OTCQX:RHHBY) will pay Ionis Pharmaceuticals Inc. (NASDAQ:IONS) $75 million up front for an option to develop and commercialize IONIS-FB-LRx, a ligand-conjugated antisense (LICA) oligonucleotide targeting complement factor B (CFB).

The partners plan to develop the candidate for complement-mediated diseases, with an initial...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >